CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
No SEC Form 4 filings for $CELZ in the last 30 days.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
Creative Medical Technology Holdings (CELZ) released a 2026 mid-year update. The company said it is advancing CELZ-201 (Olastrocel) toward Phase 3 readiness for chronic lower back pain, including completing enrollment of an expanded ADAPT cohort and seeking regulatory alignment. It also cited next-stage Ultrasome knee OA studies and early AI/partnership interest for its Biodefense Toxic Exposure Atlas. CELZ shares were down ~11.7% to $1.28.
Over the past 7 days, alphai's AI scored 1 news story mentioning CELZ (CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CELZ coverage spans financial news, market movers and corporate actions.
Patent expansion is a near-term catalyst that can sustain momentum and raise perceived IP defensibility for CELZ-101/CELZ-201 platforms.
The filing signals a new equity-linked financing/compensation structure via an inducement warrant, which can dilute holders and affect near-term risk appetite.
The update is a clinical-development progress narrative (Phase 3 readiness, enrollment completion, and regulatory alignment), which can influence near-term sentiment but lacks new trial efficacy/regulatory outcomes.
New clinical-regulatory milestones (ADAPT expansion cohort enrollment and Phase 3 planning) can shift near-term probability-weighting for Olastrocel and related partnering expectations.
Dilutive warrant exercise/financing likely supports near-term liquidity but increases share count; price reaction suggests investors are weighing funding vs dilution.
alphai scores every news story that mentions CELZ with an AI model for sentiment and relevance, and aggregates insider trades from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
3 min readCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
4 min readCreative Medical Technology Holdings (CELZ) released a 2026 mid-year update. The company said it is advancing CELZ-201 (Olastrocel) toward Phase 3 readiness for chronic lower back pain, including completing enrollment of an expanded ADAPT cohort and seeking regulatory alignment. It also cited next-stage Ultrasome knee OA studies and early AI/partnership interest for its Biodefense Toxic Exposure Atlas. CELZ shares were down ~11.7% to $1.28.
3 min readCreative Medical Technology Holdings (NASDAQ: CELZ) issued a mid-year update. It said Olastrocel (CELZ-201) has WHO-approved naming and reported positive interim 180-day ADAPT trial results; the FDA cleared an expanded cohort for patients using <90 mg/day morphine equivalents. Ultrasome™ pilot data showed a 93% primary endpoint response. The CELZ-Biodefense Atlas program advanced to nationwide AI-enabled veteran data collection.
5 min readCreative Medical Technology Holdings (CELZ) said it secured about $4.5M in gross proceeds via warrant exercises and related stock purchases. The company will exercise warrants for up to 2,790,340 shares and investors will buy 5,580,680 shares at $1.60/share, with new five-year warrants issued. Closing is expected June 30, 2026.
4 min readCreative Medical Technology Holdings (Nasdaq: CELZ) said it agreed with warrant holders to immediately exercise existing warrants for up to 2,790,340 shares at a reduced $1.60 exercise price, raising about $4.5M gross proceeds before fees. In return, it will issue new unregistered warrants for up to 5,580,680 shares at $1.60, pending shareholder approval. Closing expected June 30, 2026.
3 min readCreative Medical Technology (CELZ) said the FDA cleared an amended protocol to expand its ADAPT trial of Olastrocel (CELZ-201) for chronic lower back pain. The company will add 15 patients using <90 mg morphine equivalents/day; the new cohort is 85% enrolled and uses its AI pain-medication monitoring. Creative Medical cited positive 180-day interim results and a DSMB report of no significant adverse events, and said it is preparing for Phase 3 discussions.
3 min readCreative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announced regulatory approval for its BioDefense Inc. Burn Pit Initiative, aiming to develop a molecular and cellular database for veterans exposed to toxic burn pits. The initiative will leverage AI and iPSC technology using existing partnerships, without requiring new fundraising, despite the company's recent stock volatility and net loss. The company highlights its strong short-term liquidity with a current ratio of 20.71, as per InvestingPro data.
2 min readCreative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
3 min readSelects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform ...
4 min read
